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Abstract. The WISPs (Wnt-inducted secreted proteins,
WISP-1, WISP-2 and WISP-3) are part of the CCN family.
These molecules are known to play a diverse role in cells but
their role in cancer cells remains controversial. We analysed
the expression of the three WISP molecules at the mRNA
and protein levels in a cohort of 94 human colorectal tumours
and 80 normal colorectal tissues and correlated the results
with the pathological features and clinical outcome of the
patients. WISP-1 transcripts were found at higher levels in
the tumour samples than in the normal tissue (p=0.0015);
higher in patients with Dukes stage B and C compared to
Dukes A (p=0.017 and p=0.024, respectively); higher in
patients with moderately and poorly differentiated cancers
compared to the well differentiated cancers (p=0.020 and
p=0.076, respectively and p=0.0035 when combined); higher
in node positive tumours compared with the node negative
(p=0.11) and in the patients with higher TNM staging (TNM
2, 3 and 4 compared to TNM 1 p=0.037). WISP-2 showed
the opposite pattern with lower levels of expression in cancer
cells compared to normal (p=0.082). Although no significant
differences were found within the cancer group when indices
of a more aggressive tumour were compared to the normal
tissue a significant reduction in expression was found (Dukes
C p=0.044, poorly differentiated p=0.019, TNM 3 p=0.020
and node positive disease p=0.048). WISP-3 transcript levels
showed no significant differences between groups. WISPs
may play important but contrasting roles in colorectal cancer
with WISP-1 appearing to act as a factor stimulating aggres-
siveness, WISP-2 as a tumour suppressor and WISP-3 having
no definable beneficial or detrimental role.
Introduction
The CNN family comprises a growing number of molecules.
The first to be discovered where cysteine-rich 61 (Cyr61/
CCN1), connective tissue growth factor (CTGF/CCN2) and
nephroblastoma over-expressed (Nov/CCN3) (1). The next
to be identified were three Wnt-inducted secreted proteins
which were named WISP-1/CCN4, WISP-2/CCN5 and
WISP-3/CCN6. 
Upstream of the CCN family is Wnt-1, a cycleine-rich
glycosylated signalling protein, that was originally identifies
as an oncogene activated by the insertion of mouse mammary
tumour virus in virus induced mammary adenocarcinoma (2-4).
Although Wnt-1 has been shown to produce a significant
tumor reaction in mice the evidence of its involvement in
human cancer has not been so clearly defined. Wnt-1 is just
one of 19 Wnt proteins that are important regulators in the
signalling pathway. This pathway has diverse roles in
governing cell fate, proliferation, migration, polarity and
death. The central Wnt signalling pathway is activated by the
engagement of some of the Wnt proteins to the seven-
transmembrane spanning Frizzled receptors and recruiting the
cytoplasmic protein Dishevelled (Dsh) to the cell membrane.
Dsh inhibits kinase activity of active glycogen synthase
kinase-3ß (GSK-3ß) resulting in an increase in ß-catenin
levels. ß-catenin has been associated with colonic carcinomas
and melanomas implicating the Wnt pathway in tumouri-
genesis. 
It has been shown that three different genes are up-regulated
in Wnt-1 transformed cells WISP-1, WISP-2 and the related
gene WISP-3, all members of the CCN family of growth
factors (5). The CCN family as a whole appear to stimulate
mitosis, adhesion, apoptosis, extracellular matrix production
and migration and growth arrest (6). These functions are
probably due to the ability of the family to bind and activate
cell-surface integrins and intracellular signalling molecules
including fibulin 1C, Notch 1, S100A4 and ion channels (7).
Despite these advances in understanding the biology of the
molecules in cells and their signalling pathways their role
in cancer is unclear and no definitive results have been
reported. The WISPs have previously been implicated as
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being significant in tumourigenesis and metaplasia in a
variety of tissues. The effects are not however universal with
the proteins exerting transforming and growth stimulatory
effects on some cell types while causing inhibition of growth
and metastasis of tumour in others. 
The WISP-1 gene, which is located on the 8q24.1-8q24.3,
shows this variation of action. It has been shown that there
is an overexpression of WISP-1 RNA in colon cancer cell
lines compared to normal mucosa (5,8) and it was concluded
that WISP-1 may play a role in tumourigenesis, possibly by
promoting cell cycle checkpoint progression, accelerating
cell growth and inhibiting apoptosis. By contrast, the over
expression of WISP-1 in H460 lung cancer cells was found to
lead to an inhibition of lung metastasis and in vitro cell
invasion and motility (9). WISP-1 also protects cells from p53-
mediated apoptosis in response to DNA damage through the
activation of Akt kinase, up-regulation of Bcl-XL, and
inhibition of cytochrome c release (10). 
The WISP-2 gene, located on 20q12-20q13, has like the
other members of the CCN family, been implicated as having
an important role in both angiogenesis and carcinogenesis (6).
In contrast to WISP-1, WISP-2 DNA was amplified but its
mRNA expression was significantly reduced in the majority
of tumours compared to normal colonic mucosa suggesting it
may act as a tumour suppressor (5). This is in stark contrast
to the actions of WISP-2 in human breast disease. The
mRNA and protein levels are elevated in tumour-derived cell
lines but the levels were barely detectable in normal breast
epithelial cells. Silencing the WISP-2 gene functions also
minimizes serum-induced breast tumour cell proliferation
(11) but by contrast it can be up-regulated in non-invasive
MCF-7 human breast tumour cells by epithelial growth factor
(EGF) which is believed to be linked to poor prognosis in
breast cancer (12). 
The WISP-3 gene is located on 6q22-6q23. As seen with
WISP-1 the overexpression of WISP-3 has been linked to
colonic tumours (5,13). Previous studies concluded that
overexpression was associated with the development of
colonic tumours. Where WISP-3 differs from WISP-1 is in
the fact that there is an overexpression of WISP-3 RNA
without DNA amplification. Interesting the effects of WISP-3
in inflammatory breast cancer appears to play an important
role as a tumour suppressor gene, again the reverse of the
previous finding for colon cancer. WISP-3 has also been
linked to connective tissue disease progression in conditions
such as pseudorheumatoid dysplasia and polyjuvenile
idiopathic arthritis. It regulates the expression of cartilage-
specific molecules that sustain chondrocyte growth and
cartilage integrity by regulating collagen II, aggrecan and
possibly promote superoxide dismutase expression in the
condrocysts (14). 
The role of the WISP family in the development of clinical
cancer is unclear and in some cases controversial and
unproven. In the present study we examine the relationship
between each of the three Wnt-inducted secreted proteins
looking at their levels in a cohort of human colorectal cancer
and studied the clinical relevance. Until now these proteins
have not been studied together and directly compared in
human colorectal tumours. 
Materials and methods
Sample collection. Colorectal cancer tissue (n=94) and normal
background tissue (n=80) were collected immediately after
surgery and stored in a deep freeze until use. The presence
of tumour cells in the collection tissues was verified by a
consultant pathologist, using hematoxylin and eosin (H&E)
stained frozen sections (15,16). Details of the histology were
obtained from pathology reports and together with basic
patient demographics are shown in Table I. The study was
approved by the local ethic committee and consent was
obtained from the patients.
Materials. RNA-extraction kits and RT kits were obtained from
AbGene, Guildford, Surrey, UK. PCR primers were designed
using Beacon Designer (Palo Alto, CA, USA) and synthesized
by Invitrogen (Paisley, Scotland, UK). Molecular-biology-
grade agarose and DNA ladder were sourced from Invtrogen
while the Mastermix for routine PCR and quantitative PCR
came from AbGene (Surrey, UK). WISP-1, 2 and 3 antibodies
were purchased from Santa Cruz Biotechnologies Inc. (Santa
Cruz, CA, USA. WISP-1 (sc-8865) a goat polyclonal antibody
raised against a peptide mapping at the carboxy terminus of
WISP-1 of human origin; WISP-2 (sc-8868) goat polyclonal
antibody mapping the C-terminus of WISP-2 of human origin;
and WISP-3 (sc-25443) rabbit polyclonal antibody against
amino acids 231-295 of WISP-3 of human origin). Anti-actin
was also from Santa Cruz Biotechnologies Inc.
Tissue procession, RNA extraction and cDNA synthesis. Frozen
sections of tissue were cut to thicknesses of 5-10 μm and
kept for immunohistochemistry and routine histology (17). A
further 15-20 sections were homogenized using a hand held
device in ice-cold RNA extraction solution. The concentration
of the RNA was determined using a UV spectrophotometer.
Using an RT kit with an anchored oligo-dT primer (supplied
by AbGene) reverse transcription was carried out using 1 μg
total RNA in a 96-well plate. The quality of the cDNA was
verified using ß-actin primers.
Quantitative analysis of WISP family members. The level of
mRNA expression of WISP-1-3 from the above prepared
cDNA was determined by real-time quantitative PCR, based on
the Amplifluor™ technology (18), modified from a previously
reported method (17,19,20). A pair of PCR primers was
designed using Beacon Designer software (version 2). To
one of the primers (an antisense primer routinely used in our
laboratory) an additional sequence, known as the Z sequence
(5'-ACTGAACCTGACCGTACA-3') which is complementary
to the universal Z probe (18) (Intergen, Oxford, UK), was
added. Cytokeratin-19 (CK19) was used for comparison of
cellularity during the analysis. The primers used are given in
Table II.
The reaction was performed using: Hotstart Q-master
mix (Abgene), 10 pmol of specific forward primer, 1 pmol
of reverse primer which has the Z sequence, 10 pmol of
6-carboxyfluorescein (FAM)-tagged probe (Intergen, Oxford,
UK), and cDNA from approximately 50 ng RNA (calculated
from the starting RNA in the reverse transcriptase reaction).
The reaction was carried out using IcyclerIQ™ (Bio-Rad,
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Hemel Hempstead, UK) which is equipped with an optic unit
that allows real time detection of the 96 reactions under
the following conditions: 94˚C for 5 min, 50 cycles of: 94˚C
for 15 sec, 55˚C for 35 sec and 72˚C for 20 sec (19,21-23).
The levels of the transcripts were generated using an internal
standard (17) that was simultaneously amplified with the
samples, and are shown here in two ways: levels of transcripts
based on equal amounts of RNA, and as a target/CK19 ratio.
Immunohistochemical staining of the WISP family proteins.
The frozen sections of colorectal tumour and background
tissue were cut to a thickness of 6 μm using a cryostat (23).
The samples were mounted onto Super Frost Plus microscope
slides, air-dried and then fixed in a mixture of 50% acetone
and 50% methanol and air dried once again. Endogenous
peroxydise was block by submerging the slides in pure
ethanol/H2O2 for 15 min. The sections were then placed into
Optimax wash buffer for 20 min in a 0.6% horse serum
blocking solution and probed with the primary antibody.
Extensive washing was carried out before the sections were
incubated with the secondary biotinylated antibody (Multilink
Swine anti-goat/mouse/rabbit immunoglobulin made up in
wash buffer and horse serum to manufacturer's specification;
Vector Labs, UK) for 30 min. Following further washing,
avidin-biotin complex (Vector Latoratories, Burlingame, CA,
USA) was then applied before a final washing of the
samples. Diaminobenzidine chromogen (Vector Lab) was
then added to the sections which were then incubated in the
dark for 5 min before being counter stained in Gill's haema-
toxylin and dehydrated in ascending grades of methanol
before cleaning with xylene and mounting under a cover slip.
Statistical analysis. The statistical analysis was carried out
using the t-test (Minitab version 12.1).
Results
Expression of WISP members in colorectal tissue. Using
quantitative PCR it can be seen that WISP-1 displayed a higher
level in tumour tissues compared to normal tissue, statistically
significant at p=0.0015 (Fig. 1 left hand panel). WISP-2
displays lower levels of transcripts, just below significance
levels p=0.082 (Fig. 1 middle panel) while WISP-3, like
WISP-1 is present in greater volumes (Fig. 1 right hand panel),
however, not to a significant level p=0.86. 
Distribution of WISP members in different cell types. On
immunohistochemical analysis (Fig. 2) WISP-1 showed strong
staining of the normal epithelial cells, which was confined
mostly to the cell membrane areas with slight staining of
stromal tissue. In carcinoma tissues the staining for WISP-1
was overall found to be more intense with an increase in
cytoplasmic staining and a decrease in the staining around
the cell membrane areas, again there was slight or no stromal
staining. In contrast WISP-2 (Fig. 2 middle panel) strongly
stained in the cell membrane areas as for WISP-1, but in the
carcinoma tissues there was reduced overall staining with
very slight cell membrane or cytoplasmic staining. For
WISP-3 (Fig. 2 bottom) the staining pattern in normal tissues
was of a similar pattern as found in normal tissues stained for
WISP-1 and 2, however, in carcinoma tissues WISP-3
demonstrated more generalised cytoplasmic staining
particularly in the basal areas of the tissue again with less cell
membrane area staining and slight or no stromal staining.
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Table I. Clinical and pathological information on the study
cohort.
–––––––––––––––––––––––––––––––––––––––––––––––––
Clinical information Number (n) Percentage (%)
–––––––––––––––––––––––––––––––––––––––––––––––––
Dukes stage
A 15 19.5
B 32 41.6
C 30 39.0
T stage
T1 8 10.4
T2 10 13
T3 40 51.9
T4 19 24.7
Differentiation
Well differentiated 10 13.0
Moderately differentiated 53 68.8
Poorly differentiated 14 18.2
Nodal status
Negative 45 58.4
Positive 32 41.6
Sex
Male 49 52.1
Female 45 47.9
–––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Primer sequences for quantitative PCR. 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Forward primer Reverse primer (Z sequence underlined)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
WISP-1 CAAGAGGCCACGCAAGAC ACTGAACCTGACCGTACAGTAGGCTATGCAGTTCCTGT
WISP-2 AGTGGGGCTGGAAGGTCT ACTGAACCTGACCGTACACTCTTGGCAGAGGACGAC
WISP-3 ACAAAACAAATGCCAGCTTAT ACTGAACCTGACCGTACACATTGGTCACCCTGTTAGAT
CK19 CAGGTCCGAGGTTACTGAC ACTGAACCTGACCGTACACACTTTCTGCCAGTGTGTCTTC
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Figure 1. The level of WISP expression in human colorectal tumours compared to normal colorectal tissue.
Figure 2. Detection of WISP 1 (top), WISP-2 (middle) and WISP-3 (bottom panel) proteins in colorectal cancer cell lines using immunohistochemical
analysis. Left, normal colon tissues; middle, well differentiated carcinoma; right, Dukes B, T-4, TNM-2 tumours.
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Levels of WISP members and relationship with prognostic
indices and nodal involvement. The prognostic indices used
in this study are 2-fold; the nodal status and the Dukes
classification.
Figs. 3 and 4 show the results. From Fig. 3 it can be seen
that there are greater levels of WISP-1 expression in the node
positive tumours compared with the node negative (p=0.11,
Fig. 3 left hand panel). The reverse is true for WISP-2 in
which there are lower levels of expression in the node
positive tumours (p=0.43, Fig. 3 middle panel). WISP-3 again
has greater levels in node positive tumours (p=0.27 Fig. 3
right hand panel). There is no significant difference, however,
when the node positive tumours are compared to the normal
tissues, significant differences are found in WISP-1 levels
(p=0.034) and WISP-2 levels (p=0.048).
When comparing the WISP samples we looked at the
differences between levels of the transcript in the different
stages of the Dukes classification. The samples were
compared to both normal tissue and between the different
stages. WISP-1 had significantly different levels in both
analyses with all 3 stages having significantly greater levels
compared to the normal tissue and when compared to each
other the higher stages had the significantly greater levels
(Dukes A compared to B p=0.017, A to C p=0.024, A to B+C
combined p=0.0035 and B to C p=0.157, Fig. 4, left hand
panel). In contrast, WISP-2 showed lower levels compared to
the normal tissue and no inter-grade differences (Fig. 4,
middle panel). WISP-3 transcripts were only identified in a
few of the tumour cells and as a result differentiating
between the different groups is difficult and no significant
differences were found (Fig. 4, right hand panel).
Levels of WISP members and relationship with tumour dif-
ferentiation and the TNM staging. WISP-1 transcript was
found in higher levels in moderately and poorly differentiated
tumours compared to well differentiated tumours (p=0.020
and p=0.076, respectively and p=0.0035 when moderately
and poorly differentiated tumours were compared together,
Fig. 5 left hand panel). WISP-2 showed no significant
differences between the differentiation groups, but when they
were compared to the normal samples the poorly differentiated
patients had a significantly lower level (p=0.019, Fig. 5 middle
panel). The numbers of samples expressing WISP-3 was very
small and no significant differences were found in the limited
results (Fig. 5, right hand panel).
When looking at the TNM staging the trends show higher
levels for WISP-1 in the higher TNM stages. The differences
were not significant until the transcript levels in TNM 1 staged
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Figure 3. The level of WISP expression when comparing samples from patients with or without nodal involvement.
Figure 4. The level of WISP expression when comparing samples from patients with different Dukes staging of their colorectal cancer.
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patients were compared to the other 3 groups and a signifi-
cantly higher level was found in more diffuse disease (p=0.037,
Fig. 6 left hand panel). There were no significant differences
with WISP-2 although the levels were lower in all groups
than the normal tissues (Fig. 6 middle panel) and WISP-3
again had little data to allow significant conclusions to be
drawn (Fig. 6, right hand panel).
Discussion
This study shows an aberrant expression of the CCN family
member WISP-1, 2 and 3 in human colorectal cancer. The
results showed that there are significant clinical implications
for the patients depending on which of the WISP transcripts
are present.
This study follows on from a similar study looking at the
WISP molecules in breast cancer (25). That report concluded
that in breast cancer WISP-1 appears to act as a tumour
suppressor with transcript levels being inversely proportional
to indices of poor prognosis (positive nodal status, higher
Nottingham Prognostic Index, higher grade and poor clinical
outcome). WISP-2 by contrast was found to be associated with
aggressive tumour types with high levels found in patients
with the poorest outlook. WISP-3 showed no relationship
with prognostic indicators. The purpose of this study was to
investigate the role of the WISP molecules in colorectal
cancer to see if a similar expression pattern exists.
There were fewer transcripts of WISP-1 and WISP-3 in
tumour and normal tissue than WISP-2, however when
comparing the transcript levels to normal tissues WISP-1
and to a lesser extent WISP-3 significantly higher transcript
levels were found in tumour compared to normal tissue which
contrasted with WISP-2 which had lower levels of transcripts. 
The clinical significance of this high level of expression
of WISP-1 is most clearly seen when comparing the levels
for different Dukes grade for colorectal cancer (Fig. 4, right
hand panels). It can be seen that with increasing grade the
level of transcript significantly increases. This has clinical
implications as it has been widely reported that increasing
Dukes stage is inversely proportional to survival (26). Other
significant differences which have a clinical significance are
seen when comparing the differentiation of the tumour (Fig. 5,
right hand panel), here again we see that increased WISP-1
levels are found in moderately and poorly differentiated
tumours when compared to well differentiated tumours.
Poorly differentiated tumours have been shown to have a more
aggressive growth pattern with clinical implications. We can
conclude that WISP-1 is associated with more aggressive
colorectal cancers. The findings of increasing expression are
consistent with the early work undertaken by Pennica et al
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Figure 5. The level of WISP expression when comparing samples from patients with different grades of tumour differentiation.
Figure 6. The level of WISP expression when comparing samples from patients with different tumour, node and metastasis (TNM) scores.
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(5) that showed RNA overexpression of WISP-1 in human
colon tumours compared to normal mucosa. The same
finding were also reported by Khor et al (8) who found
increased immunohistochemical staining of WISP-1 in
colorectal cancers compared to normal tissues. In stark
contrast to Khor et al who stated that WISP-1 was associated
with well differentiated colorectal tumours we report the
opposite. The study by Khor et al was conducted on a relatively
small cohort (n=47) and did not look at other aspects of
the cancer pathology. The results are in contrast to this
department's previous findings into WISP-1 expression in
breast cancer. It was found that WISP-1 acts as a tumour
suppressor with transcript levels being inversely proportional
to tumour aggression. By contrast, it has previously been
reported that higher levels of WISP-1 were expressed in 46%
of the patients with primary breast cancer (27). WISP-1 has
also been shown to have tumour suppressive actions in H460
lung cancers (8) and in the equivalent molecule in mice,
mELM1, is down-regulated in highly metastatic mouse
melanoma cells (28). It is possible therefore that WISP-1 is a
pro-aggressive factor, or a tumour suppressor dependent on
tumour histology.
Our results for WISP-2 are in contrast to WISP-1, showing
an association between lower transcript levels in the more
aggressive tumours. Although no significant differences were
found within the cancer group when indices of a more
aggressive tumour were compared to the normal tissue a
significant reduction in expression was found (Dukes C
p=0.044, poorly differentiated p=0.019, TNM 3 p=0.020 and
node positive disease p=0.048). Our findings again confirm
the initial work on WISP-2 in colorectal cancer which also
found a reduction in RNA expression in tumours (5). There is
evidence that there is disparity in the way WISP-2 functions
in various cell types. As with colorectal cancers it has been
found that in leiomyomas WISP-2 exerted an important
function in maintaining the normal uterine phenotype and
that loss of its actions may account, at least in part, for
tumourigenesis (29). This contrasts with studies into WISP-2
in breast cancer where WISP-2 is overexpressed in the
more aggressive tumours (25), but the expression is virtually
undetected in normal mammary epithelial cell controls
(9,30). As with WISP-1, WISP-2 appears to act differently
depending on the tumour type.
The results for WISP-3 suggest that the protein behaves
as neither a promoter nor a tumour suppressor with human
breast tumours. There were no significant differences in any
of the clinically significant prognostic tests and was found in
such low levels in both normal and tumour tissues that its
involvement as a cancer modifier is unlikely. WISP-3 has
previously been described to be overexpressed in colorectal
cancers (5) and in mircosatellite instability, a phenotype of
colorectal cancers with defect mismatch repair (31), but
we have no significant data to substantiate these claims.
By contrast, WISP-3 expression is lost in the majority of
inflammatory breast cancers, a highly aggressive and metastatic
form of breast cancer (32), but when it is restored the growth
of inflammatory breast cancer cells in both in vitro and in
vivo is inhibited, therefore, WISP-3 is acting as a tumour
suppressior gene (13). It was reported that by inhibiting
WISP-3 expression in human mammary epithelial cells they
could induce epithelial-mesenchymal transition, promoting
anchorage-independent growth, motility and invasiveness,
and sensitized the cells to the growth effects of IGF-1 (14).
The pathological and clinical implications of altered WISP-3
expression remains unclear and we have not demonstrated
any significant association in colorectal cancer.
The clear contrast between each of the different WISPs
suggests very different roles for the proteins in the development
of colorectal cancer. The mechanism as to why there should
be such variation is still for the most part unclear.
In conclusion, the CNN family members WISP-1, 2 and 3
display different patterns of aberration in their expression
in human colorectal cancer. WISP-1 is clearly associated
with an aggressive tumour linked with high levels found in
the patients with the poorest prognostic outlook. In contrast
WISP-2 shows some tumour suppressive activities with the
transcript level being inversely proportional to tumour
aggression. The WISP-3 levels show no relationship with
prognostic indicators in either a protective or detrimental
way. The levels of expression were extremely low and it
can be concluded that as a clinical marker for disease it is of
little value in colorectal cancer. The contrasting expression
patterns of WISP-1 and WISP-2 may indicate a therapeutic
and prognostic role which warrants further investigation. 
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